Hyponatremia in psychiatric patients: Update on evaluation and management

Harvard Review of Psychiatry

Volumn 16, Issue 1, 2008, Pages 13-24

  Siegel, Arthur J ^a  

^a MCLEAN HOSPITAL   (United States)

Author keywords

Arginine vasopressin (AVP); AVP receptor antagonists; Hyponatremia; Osmotic demyelination syndrome; Psychogenic polydipsia; Syndrome of inappropriate secretion of antidiuretic hormone (SIADH)

Indexed keywords

ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; ARGIPRESSIN; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; CONIVAPTAN; CYCLOPHOSPHAMIDE; DESIPRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LIXIVAPTAN; NICOTINE; OMEPRAZOLE; OXCARBAZEPINE; OXYTOCIN; PHENOTHIAZINE; PLACEBO; PROSTAGLANDIN INHIBITOR; PROTON PUMP INHIBITOR; SATAVAPTAN; SEROTONIN UPTAKE INHIBITOR; SODIUM CHLORIDE; THIORIDAZINE; TOLVAPTAN; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VINCRISTINE;

ADVERSE DRUG REACTION; ASCITES; ASTHENIA; BLOOD PRESSURE; BODY WEIGHT; BRAIN DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; ELECTROLYTE BALANCE; EMERGENCY TREATMENT; FATIGUE; FLUID BALANCE; HEADACHE; HEART RATE; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; INAPPROPRIATE VASOPRESSIN SECRETION; INFUSION SITE PHLEBITIS; INFUSION SITE REACTION; LOADING DRUG DOSE; MEDICAL LITERATURE; MEDLINE; MENTAL PATIENT; MUSCLE WEAKNESS; NAUSEA; NOCTURNAL ENURESIS; ORTHOSTATIC HYPOTENSION; OSMOREGULATION; PATHOPHYSIOLOGY; PEER GROUP; PERIPHERAL EDEMA; PHLEBITIS; POLYDIPSIA; POLYDIPSIA NERVOSA; POLYURIA; PRIORITY JOURNAL; PRURITUS; PUBLICATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCHIZOPHRENIA; SERUM OSMOLALITY; SIDE EFFECT; SODIUM BLOOD LEVEL; THIRST; URINARY FREQUENCY; URINARY TRACT INFECTION; VOMITING; XEROSTOMIA;

BENZAZEPINES; DRINKING BEHAVIOR; HUMANS; HYPONATREMIA; INAPPROPRIATE ADH SYNDROME; MENTAL DISORDERS; PSYCHOTROPIC DRUGS; RECEPTORS, VASOPRESSIN; RISK FACTORS; WATER-ELECTROLYTE BALANCE;

EID: 39849089286     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.1080/10673220801924308     Document Type: Review

References (96)

1. Adrogúe HJ, Madias NE. Hyponatremia. N Engl J Med 2000;342:1581-9.
2. Kratz A, Ferraro M, Sluss PM, Lewandrowski KB. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Laboratory reference values. N Engl J Med 2004;351:1548-63.
3. Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 2007;356:2064-72.
4. Pasantes-Morales H, Lezama RA, Ramos-Mandujano G, Tuz KL. Mechanisms of cell volume regulation in hypo-osmolality. Am J Med 2006;119(7A):S4-11.
5. Sterns RH, Silver SM. Brain volume regulation in response to hypo-osmolality and its correction. Am J Med 2006;119(7A):S12-6.
6. Adrogúe HJ. Consequences of inadequate management of hyponatremia. Am J Nephrol 2005;25:240-9.
7. Nzerue CM, Baffoe-Bonnie H, You W, Falana B, Dai S. Predictors of outcome in hospitalized patients with severe hyponatremia. J Natl Med Assoc 2003;95:335-43.
8. Miller M. Syndromes of excess antidiuretic hormone release. Crit Care Clin 2001;17:11-23.
9. Fried LF, Palevsky PM. Hyponatremia and hypernatremia. Med Clin North Am 1997;81:585-609.
10. Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 2006;119:71.e1-8.
11. Decaux G. Is asymptomatic hyponatremia really asymptomatic? Am J Med 2006;119(7A):S79-82.
12. Murase T, Sugimura Y, Takefuji S, Oiso Y, Murata Y. Mechanisms and therapy of osmotic demyelination. Am J Med 2006;119(7A):S69-73.
13. Moritz ML, Ayus JC. The pathophysiology and treatment of hyponatraemic encephalopathy: an update. Nephrol Dial Transplant 2003;18:2486-91.
14. Verbalis JG. Adaptation to acute and chronic hyponatremia: implications for symptomatology, diagnosis, and therapy. Semin Nephrol 1998;18:3-19.
15. Gross P, Reimann D, Henschkowski J, Damian M. Treatment of severe hyponatremia: conventional and novel aspects. J Am Soc Nephrol 2001;12:S10-4.
16. Anderson RJ, Chung H-M, Kluge R, Schrier RW. Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med 1985;102:164-8.
17. Tierney WM, Martin DK, Greenlee MC, Zerbe RL, McDonald CJ. The prognosis of hyponatremia at hospital admission. J Gen Intern Med 1986;1:380-5.
18. Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med 2006;119(7A):S30-5.
19. de Leon J. Polydipsia. A study in a long-term psychiatric unit. Eur Arch Psychiatry Clin Neurosci 2003;253:37-9.
20. Goldman MB, Luchins DJ, Robertson GL. Mechanisms of altered water metabolism in psychotic patients with polydipsia and hyponatremia. N Engl J Med 1988;318:397-403.
21. Siegel AJ, Baldessarini RJ, Klepser MB, McDonald JC. Primary and drug-induced disorders of water homeostasis in psychiatric patients: principles of diagnosis and management. Harv Rev Psychiatry 1998;6:190-200.
22. Fraser CL, Arieff AI. Epidemiology, pathophysiology, and management of hyponatremic encephalopathy. Am J Med 1997;102:67-77.
23. Riggs AT, Dysken MW, Kim SW, Opsahl JA. A review of disorders of water homeostasis in psychiatric patients. Psychosomatics 1991;32:133-48.
24. Wong LL, Verbalis JG. Systemic diseases associated with disorders of water homeostasis. Endocrinol Metab Clin North Am 2002;31:121-40.
25. Vokes TJ, Robertson GL. Disorders of antidiuretic hormone. Endocrinol Metab Clin North Am 1988;17:281-99.
26. Kinzie BJ. Management of the syndrome of inappropriate secretion of antidiuretic hormone. Clin Pharm 1987;6:625-33.
27. Spigset O, Hedenmalm K. Hyponatraemia and the syndrome of inappropriate antidiuretic hormone secretion (SIADH) induced by psychotropic drugs. Drug Saf 1995;12:209-25.
28. Verbalis JG. Disorders of body water homeostasis. Best Pract Res Clin Endocrinol Metab 2003:17:471-503.
29. Robertson GL. Antidiuretic hormone. Normal and disordered function. Endocrinol Metab Clin North Am 2001;30:671-94.
30. Kuz GM, Manssourian A. Carbamazepine-induced hyponatremia: assessment of risk factors. Ann Pharmacother 2005;39:1943-6.
31. Decaux G, Musch W, Soupart A. Hyponatremia in the intensive care: from diagnosis to treatment. Acta Clin Belg 2000;55:69-78.
32. Bartter FC, Schwartz WB. The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med 1967;42:790-806.
33. Smith D, Moore K, Tormey W, Baylis PH, Thompson CJ. Downward resetting of the osmotic threshold for thirst in patients with SIADH. Am J Physiol Endocrinol Metab 2004;287:E1019-23.
34. Robinson AG. Disorders of antidiuretic hormone secretion. Clin Endocrinol Metab 1985;14:55-88.
35. Verbalis JG. Whole-body volume regulation and escape from antidiuresis. Am J Med 2006;119(7A):S21-9.
36. Cosgray RE, Hanna V, Davidhizar RE, Smith J. The water-intoxicated patient. Arch Psychiatr Nurs 1990;4:308-12.
37. Halmi KA. The psychobiology of eating behavior in anorexia nervosa. Psychiatry Res 1996;62:23-9.
38. Kreipe RE, Birndorf SA. Eating disorders in adolescents and young adults. Med Clin North Am 2000;84:1027-49.
39. Dong X, Leppik IE, White J, Rarick J. Hyponatremia from oxcarbazepine and carbamazepine. Neurology 2005;65:1976-8.
40. Lane RM. SSRIs and hyponatraemia. Br J Clin Pract 1997;51:144-6.
41. Perucca E, Garratt A, Hebdige S, Richens A. Water intoxication in epileptic patients receiving carbamazepine. J Neurol Neurosurg Psychiatry 1978;41:713-8.
42. Siegler EL, Tamres D, Berlin JA, Allen-Taylor L, Strom BL. Risk factors for the development of hyponatremia in psychiatric inpatients. Arch Intern Med 1995;155:953-7.
43. Bachu K, Godkar D, Gasparyan A, Sircar P, Yakoby M, Niranjan S. Aripiprazole-induced syndrome of inappropriate antidiuretic hormone secretion (SIADH). Am J Ther 2006;13:370-2.
44. Covyeou JA, Jackson CW. Hyponatremia associated with escitalopram. N Engl J Med 2007;356:94-5.
45. Jacob S, Spinler SA. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. Ann Pharmacother 2006;40:1618-22.
46. U.S. Food and Drug Administration Center for Drug Evaluation and Research. FDA Alert. Desmopressin acetate (marketed as DDAVP Nasal Spray, DDAVP Rhinal Tube, DDAVP, DDVP, Minirin, and Stimate Nasal Spray). December 4, 2007. At: http://www.fda.gov/cder/drug/infopage/desmopressin/default.htm
47. Robertson GL. Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis. Am J Med 2006;119(7A):S36-42.
48. Goldman MB, Robertson GL, Luchins DJ, Hedeker D. The influence of polydipsia on water excretion in hyponatremic, polydipsic, schizophrenic patients. J Clin Endocrinol Metab 1996;81:1465-70.
49. Goldman MB, Robertson GL, Luchins DJ, Hedeker D, Pandey GN. Psychotic exacerbations and enhanced vasopressin secretion in schizophrenic patients with hyponatremia and polydipsia. Arch Gen Psychiatry 1997;54:443-9.
50. Kawai N, Baba A, Suzuki T, Shiraishi H. Roles of arginine vasopressin and atrial natriuretic peptide in polydipsia-hyponatremia of schizophrenic patients. Psychiatry Res 2001;101:39-45.
51. Hartung TK, Schofield E, Short AI, Parr MJ, Henry JA. Hyponatraemic states following 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') ingestion. QJM 2002;95:431-7.
52. Siegel AJ, Verbalis JG, Clement S, et al. Exertional hyponatremia in marathon runners is associated with inappropriate secretion of arginine vasopressin. Am J Med 2007;120:461.e11-7.
53. Palm C, Pistrosch F, Herbrig K, Gross P. Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia. Am J Med 2006;119:S87-92.
54. Soupart A, Decaux G. Therapeutic recommendations for management of severe hyponatremia: currents concepts on pathogenesis and prevention of neurologic complications. Clin Nephrol 1996;46:149-69.
55. Gullans SR, Verbalis JG. Control of brain volume during hyperosmolar and hypoosmolar conditions. Annu Rev Med 1993;44:289-301.
56. Leadbetter RA, Shutty MS Jr, Higgins PB, Pavalonis D. Multidisciplinary approach to psychosis, intermittent hyponatremia, and polydipsia. Schizophr Bull 1994;20:375-85.
57. Velligan DI, Miller AL. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment. J Clin Psychiatry 1999;60(suppl 23):25-8.
58. Collaborative Working Group on Clinical Trial Evaluations. Measuring outcome in schizophrenia: differences among the atypical antipsychotics. J Clin Psychiatry 1998;59(suppl 12):3-9.
59. Nicolson SE, Mayberg HS, Pennell PB, Nemeroff CB. Persistent auditory hallucinations that are unresponsive to antipsychotic drugs. Am J Psychiatry 2006;163:1153-9.
60. Paterniti S, Dufouil C, Bisserbe J-C, Alpérovitch A. Anxiety, depression, psychotropic drug use and cognitive impairment. Psychol Med 1999;29:421-8.
61. Stordal KI, Lundervold AJ, Mykletun A, et al. Frequency and characteristics of recurrent major depressed patients with unimpaired executive function. World J Biol Psychiatry 2005;6:36-44.
62. Keks NA. Impact of newer antipsychotics on outcomes in schizophrenia. Clin Ther 1997;19:148-58.
63. Gorman JM. Treating generalized anxiety disorder. J Clin Psychiatry 2003;64(suppl 2):24-9.
64. Weiden PJ, Miller AL. Which side effects really matter? Screening for common and distressing side effects of antipsychotic medications. J Psychiatr Pract 2001;7:41-7.
65. Vieweg WV. Treatment strategies in the polydipsia-hyponatremia syndrome. J Clin Psychiatry 1994;55:154-60.
66. Han D-S, Cho B-S. Therapeutic approach to hyponatremia. Nephron 2002;92(suppl 1):9-13.
67. Milionis HJ, Liamis GL, Elisaf MS. The hyponatremic patient: a systematic approach to laboratory diagnosis. CMAJ 2002;166:1056-62.
68. Baylis PH. The syndrome of inappropriate antidiuretic hormone secretion. Int J Biochem Cell Biol 2003;35:1495-9.
69. Siegel AJ. Exercise-associated hyponatremia: role of cytokines. Am J Med 2006;119(7A):S74-8.
70. Cawley MJ. Hyponatremia: current treatment strategies and the role of vasopressin antagonists. Ann Pharmacother 2007;41:840-50.
71. Thurman JM, Halterman RK, Berl T. Therapy of dysnatremic disorders. In: Brady HR, Wilcox CS, eds. Therapy in Nephrology and Hypertension. 2nd ed. London: Sanders, 2003:334-48.
72. Hew-Butler T, Almond C, Ayus JC, et al. for the Exercise-Associated Hyponatremia (EAH) Consensus Panel. Consensus statement of the 1st International Exercise-Associated Hyponatremia Consensus Development Conference, Cape Town, South Africa, 2005. Clin J Sport Med 2005;15:208-13.
73. Ayus JC, Arieff A, Moritz ML. Hyponatremia in marathon runners [Letter]. N Engl J Med 2005;353:427.
74. Siegel AJ. Hypertonic (3%) sodium chloride for emergent treatment of exercise-associated hypotonic encephalopathy. Sports Med 2007;37:459-62.
75. Lampl C, Yazdi K. Central pontine myelinolysis. Eur Neurol 2002;47:3-10.
76. Tanneau RS, Henry A, Rouhart F, et al. High incidence of neurologic complications following rapid correction of severe hyponatremia in polydipsic patients. J Clin Psychiatry 1994;55:349-54.
77. Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007;120(11A):S1-21.
78. Goldman MB, Nash M, Blake L, Petkovic MS. Do electrolyte-containing beverages improve water imbalance in hyponatremic schizophrenics? J Clin Psychiatry 1994;55:151-3.
79. Canuso CM, Goldman MB. Clozapine restores water balance in schizophrenic patients with polydipsia-hyponatremia syndrome. J Neuropsychiatry Clin Neurosci 1999;11:86-90.
80. Wakefield T, Colls I. Clozapine treatment of a schizophrenic patient with polydipsia and hyponatremia. Am J Psychiatry 1996;153:445-6.
81. Verghese C, Abraham G, Nair C, et al. Absence of changes in antidiuretic hormone, angiotensin II, and atrial natriuretic peptide with clozapine treatment of polydipsia-hyponatremia: 2 case reports. J Clin Psychiatry 1998;59:415-9.
82. Fuller MA, Jurjus G, Kwon K, Konicki E, Jaskiw GE. Clozapine reduces water-drinking behavior in schizophrenic patients with polydipsia. J Clin Psychopharmacol 1996;16:329-32.
83. Spears NM, Leadbetter RA, Shutty MS Jr. Clozapine treatment in polydipsia and intermittent hyponatremia. J Clin Psychiatry 1996;57:123-8.
84. Goldman MB, Hussain N. Absence of effect of olanzapine on primary polydipsia: results of a double-blind, randomized study. J Clin Psychopharmacol 2004;24:678-80.
85. Gheorghiade M, Gattis WA, Barbagelata A, et al. Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. Am Heart J 2003;145:S51-4.
86. Verbalis JG, Ghali JK, Gross P, Long WA, Smith N. Efficacy and safety of the vasopressin antagonist conivaptan in patients with euvolemic hyponatremia evaluated in a phase III clinical trial. J Clin Oncol 2006;24(suppl 18S):480S.
87. Verbalis JG, Rosansky S, Wagoner LE, Smith N, Barve A, Andoh M. Conivaptan for the treatment of hyponatremia in hospitalized patients: results from an open-label study [Abstract]. Crit Care Med 2007;34(suppl):A64.
88. Ghali JK, Koren MJ, Taylor JR, et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 2006;91:2145-52.
89. Schrier RW, Gross P, Gheorghiade M, et al. for the SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-112.
90. Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure. Results from a double-blind, randomized trial. Circulation 2003;107:2690-6.
91. Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure. A randomized controlled trial. JAMA 2004;291:1963-71.
92. Wong F, Blei AT, Blendis LM, Thuluvath PJ, for the North American VPA-985 Study Group. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003;37:182-91.
93. Soupart A, Gross P, Legros JJ, et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol 2006;1:634-40.
94. Abraham W, Koren M, Bichet DG, et al. Treatment of hyponatremia in patients with SIADH or CHF with intravenous conivaptan (YM087), a new combined vasopressin V1A/V2 receptor antagonist, abstract. Eur Heart J 2000;21(abstr suppl):345.
95. Josiassen RC, Goldman M, Jessani M, Shaughnessy RA, Czerwiec FS, Orlandi C. Vasopressin V2-receptor blockade with tolvaptan in schizophrenic patients with hyponatremia: results from a double-blind, randomized trial [Abstract]. Schizophr Bull 2007;33:434.
96. Vaprisol® (conivaptan hydrochloride injection). Prescribing information. Deerfield, IL: Astellas Pharma US, Inc., February 2007.